Software Equity Group

MAY 8, 2024

2023 saw a myriad of factors impact SaaS M&A multiples, including economic developments, technological advancements, and a public market rebound. In any given year, however, some sectors of the SaaS universe are more prosperous than others, depending on industry trends, global economics, and other influences.

M&A 52

M&A Valuation Economics Business 52

Software Equity Group

MAY 7, 2024

2023 saw a myriad of factors impact SaaS M&A multiples, including economic developments, technological advancements, and a public market rebound. In any given year, however, some sectors of the SaaS universe are more prosperous than others, depending on industry trends, global economics, and other influences.

M&A 52

M&A Valuation Economics Business 52

Wall Street Mojo

FEBRUARY 9, 2024

When listed as publicly traded companies, they mostly become small-cap and micro-cap stocks trading on the exchange. At the same time, lower middle market private equity firms are more interested in this segment because of the variety of firms they get to seek across different sectors and industries.

Middle Market 52

Middle Market Bulge Bracket Private Equity Investment Banking 52

How2Exit

OCTOBER 2, 2023

rn Businesses can increase their value by working with professionals who can help them reach higher revenue thresholds and attract private equity firms. Industries such as veterinarian services, pet services, and health services are particularly attractive to buyers due to their resilience in the face of economic downturns.

Mergers and Acquisitions 130

Mergers and Acquisitions Business M&A Mergers 130

Focus Investment Banking

AUGUST 6, 2023

ESG isn’t just a matter for large, publicly traded companies. While many people see this as merely “doing the right thing,” there is also often an economic payoff. This is particularly true if your partners are publicly traded or foreign-owned. It’s increasingly becoming a must for small and medium-sized businesses.

Middle Market 52

Middle Market Business Government Profitability 52

Intrepid Banker Insights

MARCH 28, 2023

Intrepid Investment Bankers Warning Signs Your Business’s Liquidity Needs Attention Mixed signals dominate economic headlines as concerns persist about a recession beginning in 2023, if it has not already begun. At the same time, employment remains strong, with the unemployment rate hitting an all-time low.

Capital 52

Capital Advisory Bank Banking 52

Software Equity Group

FEBRUARY 28, 2023

Stock prices and valuations of many leading public SaaS companies have fallen drastically from the beginning of 2022—but while that will affect the private market, it does not necessarily spell doom and gloom. This post will examine the current state of public SaaS company valuations and what it means for private companies.

Valuation 52

Valuation M&A Stock Business 52

Cooley M&A

SEPTEMBER 16, 2022

In addition, currently public dual-class companies with transfer provisions that do not contain clear carve outs for the delivery of voting agreements in the M&A context should discuss with their advisers the possibility of adopting “clear day” amendments to their charters to include these carve outs. Vote-down termination fee (i.e.,

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Software Equity Group

OCTOBER 22, 2024

In today’s economic climate, retention is everything: Software companies with Net Revenue Retention (NRR) rates above 120% are trading at a remarkable 63% premium over the market median. Because in a world where growth is uncertain, retaining and expanding existing customers is the ultimate competitive advantage.

Valuation 52

Valuation Investors IT Management 52

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. There is a history of drugs failing for one use and then being successfully developed for other uses.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40